Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 01:30:00 11/04/2026 am IST			5-day change	1st Jan Change
21.18 ^USD	-4.72%		-8.82%	-1.58%

07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT

Transcript : Sarepta Therapeutics, Inc., Q4 2025 Earnings Call, Feb 25, 2026

Published on 02/26/2026 at 10:51 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon, and welcome to Sarepta's Fourth Quarter 2025 Earnings Results Call. As a reminder, today's program is being recorded.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT
26/03	Wedbush Raises Price Target on Sarepta Therapeutics to $35 From $29, Keeps Outperform Rating	MT
26/03	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
25/03	Top Midday Gainers	MT
25/03	Sarepta Therapeutics, Inc. - Special Call
25/03	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI
25/03	Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases	MT
25/03	Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1	RE
19/03	Sarepta Therapeutics Plans to Submit Supplemental New Drug Applications for Amondys 45, Vyondys 53	MT
19/03	Sarepta Therapeutics Provides Regulatory Update On Amondys 45 And Vyondys 53	CI
19/03	Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value	CI
16/03	Sarepta Begins Enrollment in Study Evaluating Safety Regimen With Duchenne Therapy	MT
16/03	Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne	RE
16/03	Sarepta Announces That Screening and Enrollment Are Underway in Endeavor Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI